We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go: Extended investment: £10,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
HaMuch is an online platform that lets homeowners compare hourly rates of local tradespeople and check their availability. The company has provided digital marketing services to businesses such as Travis Perkins, HomeServe, and Rated People. About 200,000 tradespeople have uploaded their profiles on the platform with 12,000+ having uploaded their respective prices. The company has been featured in The Sunday Telegraph, Express, Sun, and Microsoft News. 

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £132,850
Plug-N-Go is a company that provides electric vehicle charging infrastructure with the aim of sustainably electrifying transport. The company has 24 charge points that are accessible to users via its app. It sources 100% renewable energy from its partners at Octopus Energy. Air pollution is contributing to 40,000 early deaths a year in the UK that Plug-N-Go is striving to change. The global electric vehicle charging stations market will reach USD 27.7 billion by 2027 from an estimated USD 2.5 billion in 2019. The company hopes to become a strong contender in this segment. Plug-N-Go is in discussions over multi-site agreements with the Co-operative Society and Eden district council and has received interest from Associated British Ports. Its goal is to install 3,800 EV charge points for the public in 5 years at sites where drivers are already parking. The company will use the investment to deliver EV charging stations to businesses across the UK.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £176,008
Milbotix, a healthtech start-up, supported by the Alzheimer's Society and the UK Dementia Research Institute, is driven by its innovative product SmartSocks™. This wearable technology aims to assist individuals with dementia facing communication challenges and their caregivers. Globally, the number of people with dementia is increasing significantly, reaching 78 million by 2030 and 139 million by 2050. Half of those diagnosed with dementia encounter challenging behavioral symptoms due to distress. Early distress management not only enhances well-being but also helps prevent escalating behavioral issues. SmartSocks™ utilize sensors and artificial intelligence to notify dementia caregivers about early signs of pain and anxiety in their patients.
days to go: Expired investment: £220,780
FloatWind manufactures mass-produced floating offshore wind turbines. It seeks to disrupt the £20 billion offshore wind energy market. The company argues that conventional offshore wind farms, installed at sea, use expensive and slow installation methods that are also dangerous to the marine environment. It further stresses that the high cost of installation is often borne by the consumer. FloatWind asserts that its business model is different. The company claims to build its products on land and then floats its ready-to-float turbines out to sea. The company points out that this reduces environmental damage, substantially reduces costs, and makes offshore wind energy cheaper. FloatWind was selected for a 6-month UK Innovate Edge business mentoring programme and appeared for SetSquared Business Mentoring Seminar in May 2021. The company has 3,000+ followers on LinkedIn. FloatWind states it will use the investment for product development, expanding its team, IP protection, promoting marketing and PR, and boosting its manufacturing capabilities.
days to go: Expired investment: £311,497
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph